Ranbaxy Laboratories

Lowey Dannenberg, P.C. and The Dugan Law Firm, APLC Announce Court's Certification of Class Action Involving Third-Party Payors' Payment or Reimbursement for Some or All of the Purchase Price of Generic Nexium (esomeprazole magnesium), Brand or Generic Di

Retrieved on: 
Friday, November 5, 2021
Nexium, Valsartan, Person, South African Class ES, City, Pharmacy, AB, Plasma protein binding, Insurance, MDL Information Systems, TPP Nikola Tesla, Judgement, Ranbaxy Laboratories, John Joseph Moakley United States Courthouse, Maryland Office of the Public Defender, Court, MDL, District, FDA, TPP, Generic drug, Health insurance, Pharmaceutical industry, Maple syrup

Your rights may be affected by a class action lawsuit regarding the price paid for generic Nexium, brand and generic Diovan, and brand and generic Valcyte by Third-Party Payors ("TPPs") filed against Defendants Sun Pharmaceutical Industries, Ltd. And Ranbaxy, Inc.

Key Points: 
  • Your rights may be affected by a class action lawsuit regarding the price paid for generic Nexium, brand and generic Diovan, and brand and generic Valcyte by Third-Party Payors ("TPPs") filed against Defendants Sun Pharmaceutical Industries, Ltd. And Ranbaxy, Inc.
  • The case name is In Re Ranbaxy Generic Drug Application Antitrust Litigation, MDL No.
  • You are a member of the Class(es) if you are a TPP and you purchased or provided reimbursement for prescription drugs as described as follows:
    Generic Nexium Nationwide Class.
  • Any changes to the date or location of the trial will be posted to the case website.

Information Update - Certain Metformin diabetes drugs recalled due to the presence of NDMA

Retrieved on: 
Wednesday, February 26, 2020
Drugs, RTT, Biguanides, Guanidines, Metformin, Ranbaxy Laboratories, Combination drugs, Diabetes management

What to do:You should not stop taking your metformin drug without first discussing options with your health care provider.

Key Points: 
  • What to do:You should not stop taking your metformin drug without first discussing options with your health care provider.
  • Please refer to the Affected products table below for detailed information on the recalled lots.
  • The risks from not having adequate diabetes treatment outweigh any possible effects of exposure to the levels of NDMA found in the recalled products.
  • Ranbaxy Pharmaceuticals Canada Inc. by calling toll-free at 1-866-840-1340, or by email at [email protected]
    The following is a list of metformin drugs being recalled in Canada at this time:

Dinesh Thakur and Erin Fox Call on U.S. Congress and FDA to Hold Hearings on Generic Drug Safety in America in Wake of Explosive New Book "Bottle of Lies"

Retrieved on: 
Tuesday, May 14, 2019
Health, Articles, Pharmaceuticals policy, CNX Nifty, Pharmaceutical industry, Ranbaxy Laboratories, Generic drug, Pharmacovigilance

Six years ago, drug supply chain expert Dinesh Thakur was a historic whistleblower who took on Goliath pharmaceutical manufacturer Ranbaxy in India and won.

Key Points: 
  • Six years ago, drug supply chain expert Dinesh Thakur was a historic whistleblower who took on Goliath pharmaceutical manufacturer Ranbaxy in India and won.
  • "The new book 'Bottle of Lies' exposes the truth and it is critical that Congress hold hearings to address generic drug safety in America."
  • Dinesh Thakur's extensive background includes senior positions within the pharmaceutical drug industry, generic drug manufacturers, and as an entrepreneur and service provider to the industry.
  • Her work focuses on the role product quality plays in drug shortages which are a key contributor to drug pricing.

Global $200+ Billion Drug API Market Forecasts to 2024 with Teva Pharmaceutical Industries, Dr. Reddy's Laboratories, Aurobindo Pharma and Cipla Dominating

Retrieved on: 
Wednesday, April 24, 2019
Companies, Pharmaceutical companies, CNX Nifty, Economy of India, Science and technology in Israel, BSE SENSEX, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries, Cipla, Pharmaceutical industry, Aurobindo Pharma, Ranbaxy Laboratories

DUBLIN, April 24, 2019 /PRNewswire/ -- The "Drug API Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 24, 2019 /PRNewswire/ -- The "Drug API Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The global drug API market is projected to grow at a CAGR of 5.40% to reach US$200.385 billion by 2024, from US$146.141 billion in 2018.
  • The rising R&D expenditure, growing pharmaceutical industry is driving the growth of the global drug API market in the forecast period.
  • Major industry players profiled as part of the report are Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma and Cipla Inc. among others.

Exelixis’ Collaborator Daiichi Sankyo Receives Regulatory Approval For MINNEBRO™ (Esaxerenone) Tablets for the Treatment of Hypertension in Japan

Retrieved on: 
Tuesday, January 8, 2019
Health, Biotechnology, Cardiology, Clinical trials, Pharmaceutical, Daiichi Sankyo, Economy of Japan, Exelixis, Dai-ichi, Business, Stock market, Ranbaxy Laboratories

MINNEBRO is a compound identified during the prior research collaboration between Exelixis and Daiichi Sankyo, which the companies entered into in March 2006, and has been subsequently developed by Daiichi Sankyo.

Key Points: 
  • MINNEBRO is a compound identified during the prior research collaboration between Exelixis and Daiichi Sankyo, which the companies entered into in March 2006, and has been subsequently developed by Daiichi Sankyo.
  • We congratulate our partner Daiichi Sankyo on their superb clinical development program and recent approval.
  • Per the collaboration agreement between Exelixis and Daiichi Sankyo, Exelixis will receive a $20 million milestone payment upon the first commercial sale of MINNEBRO in Japan.
  • During this same time period, the company entered into the research collaboration with Daiichi Sankyo that led to MINNEBRO.

Cipher Pharmaceuticals Announces Amended Distribution and Supply Agreement for Absorica®

Retrieved on: 
Monday, July 30, 2018
CNX Nifty, Economy of India, Isotretinoin, Retinoids, Ranbaxy Laboratories, Sun Pharmaceutical, Pharmaceutical industry, Health care

MISSISSAUGA, ON, July 30, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it has amended its distribution and supply agreement (the "Amendment") with Sun Pharmaceutical Industries, Inc. ("Sun") (previously Ranbaxy Laboratories Inc.) for Absorica, an innovative formulation of the active ingredient isotretinoin, which is used in the treatment of severe acne.

Key Points: 
  • MISSISSAUGA, ON, July 30, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it has amended its distribution and supply agreement (the "Amendment") with Sun Pharmaceutical Industries, Inc. ("Sun") (previously Ranbaxy Laboratories Inc.) for Absorica, an innovative formulation of the active ingredient isotretinoin, which is used in the treatment of severe acne.
  • Under the original agreement, entered in August 2008, Cipher granted Sun the exclusive right to market, sell and distribute Absorica in the United States ("U.S.").
  • "This is a significant milestone for Cipher, providing the opportunity to maximize our total cumulative revenues from Absorica and other isotretinoin products.
  • Cipher (TSX:CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.